Het Van Weel-Bethesda Ziekenhuis

Dirksland 22 trials 6 recruiting

22 Registered trials

6 Currently recruiting

Organisation

Het Van Weel-Bethesda Ziekenhuis

Location

Dirksland, Netherlands

Identifier

ORG-100045472

Address

Stationsweg 22, 3247 BW, Netherlands

Departments

#2919:Cardiology
Cardiologie
Cardiology
Endocrinologie
Intensive Care
Internal Medicine/oncology
Interne geneeskunde
Longziekten
N/A
Neurology
Oncology
Van Weel-Bethesda

Clinical trials at this site (22)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCL… Pending

2025-520792-67-00 Patients with advanced, metastatic NSCLC that have not 5
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
BuLLSEYE Recruiting

2024-512950-13-00 Sepsis 11 2025-01-03
Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting

2024-514927-40-02 Chronic Subdural Hematoma 11 2024-10-01
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 4 2019-04-09
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24